EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Liver Transplant for Hepatic Epithelioid Hemangioendothelioma

Emily L Larson iD, Yusuf Ciftci, Reed T Jenkins iD, Alice L Zhou iD, Jessica M Ruck iD, Benjamin Philosophe

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Emily L Larson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transplantation Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Liver Transplantation, Hemangioendothelioma, Epithelioid, Liver Neoplasms, Postoperative Complications. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Johns Hopkins Department of Surgery.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatic epithelioid hemangioendothelioma (HEH) is a rare indication of liver transplant with limited evidence.

Methods

Adult recipients undergoing first‐time liver‐only transplant from 2002 to 2021 in the United States were identified using the UNOS/OPTN database. We compared post‐transplant outcomes of recipients receiving liver transplant for HEH versus other diagnoses. Survival was visualized using Kaplan‐Meier curves and compared using log‐rank test and multivariable Cox regression. Propensity score matching for recipient age, sex, and MELD was performed, with baseline characteristics and survival compared between groups.

Results

Of 111 558 liver transplant recipients identified, 121 (0.1%) underwent transplant for HEH. Donors to HEH recipients were more often living donors. Recipients with HEH were younger, more likely to be female, and had lower BMI. Recipients with HEH had higher albumin, lower bilirubin, lower INR, and lower serum creatinine, as well as lower MELD scores and rates of ascites and encephalopathy. Similar post‐transplant survival was observed for recipients with HEH (16.6 [lower 95% CI 14.9] years) and non‐HEH diagnoses (13.8 [95% CI 13.6–13.9] years, log‐rank p = 0.28), even after adjusting for baseline donor and recipient characteristics (aHR 1.28 [95% CI 0.94–1.74], p = 0.12). The propensity score matched cohort also had similar post‐LT survival.

Conclusions

This national study represents the largest known report on liver transplant for HEH. The survival of recipients with HEH was similar to other etiologies, supporting the use of liver transplantation (LT) in advanced HEH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationHemangioendothelioma, EpithelioidLiver NeoplasmsPostoperative ComplicationsGraft RejectionHumansFemaleMaleMiddle AgedFollow-Up StudiesPrognosisSurvival RateGraft SurvivalAdultRetrospective StudiesRisk FactorsPropensity Score

Stichwörter der Autor:innen

hepatic epithelioid hemangioendotheliomaliver transplantationtransplant oncology

Autor:innen und Institutionen

  • Division of Transplantation Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.

ORCID-Profile: Emily L Larson, Reed T Jenkins, Alice L Zhou, Jessica M Ruck

Förderung

  • Johns Hopkins Department of Surgery

Zitieren

APA

Larson, E. L., Ciftci, Y., Jenkins, R. T., Zhou, A. L., Ruck, J. M., & Philosophe, B. (2025). Outcomes of Liver Transplant for Hepatic Epithelioid Hemangioendothelioma. Clinical Transplantation. https://doi.org/10.1111/ctr.70087

Vancouver

Larson EL, Ciftci Y, Jenkins RT, Zhou AL, Ruck JM, Philosophe B. Outcomes of Liver Transplant for Hepatic Epithelioid Hemangioendothelioma. Clinical Transplantation. 2025. doi:10.1111/ctr.70087

BibTeX
@article{Larson2025,
  author = {Larson, Emily L and Ciftci, Yusuf and Jenkins, Reed T and Zhou, Alice L and Ruck, Jessica M and Philosophe, Benjamin},
  title = {Outcomes of Liver Transplant for Hepatic Epithelioid Hemangioendothelioma},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70087}
}
Kostenlos starten →